A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease

Matthew R. Weir,Pablo E. Pergola,Rajiv Agarwal,Jeffrey C. Fink,Nelson Kopyt,Ajay K. Singh,Jayant Kumar,Susanne Schmitt,Gregor Schaffar,Anita Rudy,Jim P. McKay,Radmila Kanceva

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease

2017

Matthew R. Weir
Pablo E. Pergola
Rajiv Agarwal
Jeffrey C. Fink
Nelson Kopyt
Ajay K. Singh
Jayant Kumar
Susanne Schmitt
Gregor Schaffar
Anita Rudy
Jim P. McKay
Radmila Kanceva

Background: HX575 (biosimilar epoetin alfa) was approved in Europe in 2007 for the treatment of chronic kidney disease (CKD)-related anemia. This study assessed t

Keywords:

Dialysis
Biosimilar
Epoetin alfa
Anemia
Kidney disease
Disease
Medicine
end stage renal disease
Hemodialysis
Endocrinology
Internal medicine
Peritoneal dialysis
Clinical endpoint
Gastroenterology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations